Latest On Zealand Pharma A/S (ZEAL):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2022-11-10 10:48 EST | News | Zealand Pharma reports nine-month results | N/A |  |
| 2022-10-05 01:47 EST | News | Zealand Pharma announces private placement of 4.5M new shares | N/A | |
| 2022-09-30 11:48 EST | News | Zealand says short bowel syndrome therapy reached main goal in Phase 3 trial | N/A | |
| 2022-09-07 12:16 EST | News | Novo Nordisk to pay DKK25M upfront to Zealand Pharma in license deal for Zegalogue | N/A | |
| 2022-08-24 14:58 EST | News | Zealand Pharma appoints CFO | N/A | |
About Zealand Pharma A/S (ZEAL):
Zealand Pharma A/S, a biotechnology company, engages in the discovery and development of peptide-based medicines in Denmark. It has a portfolio of medicines in development stage focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide under the brand names of Adlyxin, Lyxumia, Soliqua 100/33, and Suliqua. Its product pipeline includes glepaglutide, a long acting GLP-2 analog, which is in Phase 3 clinical trials for the treatment of short bowel syndrome; and dasiglucagon, a stable glucagon analog for the treatment of severe hypoglycemia in diabetes and congenital hyperinsulinism, as well as for use in dual-hormone artificial pancreas for automated diabetes management. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringe read more...r Ingelheim International GmbH; and Beta Bionics, Inc. to initiate home-use trial of the iLet bionic pancreas with dasiglucagon for autonomous bihormonal treatment of type 1 diabetes, as well as research agreement with Orbit Discovery Ltd. and Torrey Pines Institute for Molecular Studies. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.
General
- Name Zealand Pharma A/S
- Symbol ZEAL
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 329
- Fiscal Year EndDecember
- IPO Date2017-08-09
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.zealandpharma.com
Valuation
- Trailing PE 10.13
- Price/Sales (Trailing 12 Mt.) 20.68
- Price/Book (Most Recent Quarter) 7.01
- Enterprise Value Revenue 3.26
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$4.20
- Next Year EPS Estimate -$3.64
- Profit Margin -240%
- Return on Assets -30%
- Return on Equity -69%
- Earnings Per Share $3.00
- Revenue Per Share $0
- Gross Profit 262.75 million
- Quarterly Earnings Growth 451.3%
Highlights
- Market Capitalization 1.31 billion
- Analyst Target Price $39.59
- Book Value Per Share $6.32
Share Statistics
- Shares Outstanding 43.34 million
- Shares Float 30.68 million
- % Held by Insiders 1%
- % Held by Institutions 4.24%
- Shares Short 154865
- Shares Short Prior Month 104811
- Short Ratio 7.4
Technicals
- Beta 0.94
- 52 Week High $44.42
- 52 Week Low $26.82
- 50 Day Moving Average 32.58
- 200 Day Moving Average 36.11
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Zealand Pharma A/S (ZEAL) Dividend Calendar:
Zealand Pharma A/S (ZEAL) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Zealand Pharma A/S (ZEAL) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Zealand Pharma A/S (ZEAL) Chart:
Zealand Pharma A/S (ZEAL) News:
Below you will find a list of latest news for Zealand Pharma A/S (ZEAL) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Zealand Pharma A/S (ZEAL) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Zealand Pharma A/S (ZEAL) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-09-30 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-09-22 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-09-16 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-09-16 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-09-08 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-09-02 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-08-25 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-08-14 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-07-06 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-06-30 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-06-30 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-06-25 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-06-25 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-06-24 | CT ORDER (Confidential treatment order) | |
| 2020-06-22 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-06-18 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-06-16 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-06-15 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-05-29 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-05-29 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |